Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors
Table 2
Antiretroviral treatment exposure of 80 HIV-infected adolescents receiving protease inhibitor- (PI-) based highly active antiretroviral therapy (HAART).
HAART exposure
Current HAART regimen, (%)
(i) 2NRTI + boosted PI
72 (90.0)
(ii) NRTI + NNRTI + boosted PI
8 (10.0)
Antiretroviral drugs currently being received, (%)
(i) Abacavir
1 (1.3)
(ii) Didanosine
3 (3.8)
(iii) Lamivudine
79 (98.8)
(iv) Tenofovir
55 (68.8)
(v) Zidovudine
22 (27.5)
(vi) Efavirenz
11 (13.8)
(vii) Nevirapine
1 (1.3)
(viii) Lopinavir/ritonavir
48 (60.0)
(ix) Atazanavir/ritonavir
24 (30.0)
(x) Darunavir/ritonavir
8 (10.0)
Duration of PI (months), median (IQR)
72.6 (56.1–81.2)
Duration of HAART (months), median (IQR)
114.3 (78.8–129.6)
Cumulative duration of antiretroviral drug ever received (months), median (IQR)
(i) Didanosine
29.8 (0–65.3)
(ii) Stavudine
21.1 (0–51.3)
(iii) Tenofovir
20.0 (3.8–41.4)
(iv) Zidovudine
59.7 (31.3–82.6)
(v) Efavirenz
13.8 (0–35.8)
(vi) Nevirapine
0.4 (0–28.8)
(vii) Lopinavir/ritonavir
51.5 (28.7–71.7)
(viii) Atazanavir
0 (0–8.8)
(ix) Darunavir
0 (0-0)
(x) Indinavir
6.3 (0–37.2)
(xi) Full dose ritonavir
0 (0-0)
Number of patients ever received the antiretroviral drug for ≥ 6 months, (%)
(i) Didanosine
56 (70.0)
(ii) Stavudine
51 (63.7)
(iii) Tenofovir
57 (71.3)
(iv) Zidovudine
73 (91.3)
(v) Efavirenz
43 (53.7)
(vi) Nevirapine
34 (42.5)
(vii) Lopinavir/ritonavir
79 (98.8)
(viii) Atazanavir
23 (28.8)
(ix) Darunavir
13 (16.3)
(x) Indinavir
40 (50.0)
(xi) Full dose Ritonavir
8 (10.0)
Includes those not receiving the drug. Stavudine and indinavir were no longer in use after mid-2011. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; IQR, interquartile range.
